Avalo Therapeutics AVTX Business Segments — Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherExpenses.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's business segments — other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's business segments — other?
- Avalo Therapeutics (AVTX) reported business segments — other of $70K in Q1 2026.
- How has Avalo Therapeutics's business segments — other changed year-over-year?
- Avalo Therapeutics's business segments — other increased by 16.7% year-over-year, from $60K to $70K.
- What is the long-term trend for Avalo Therapeutics's business segments — other?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — other has grown at a 4.1% compound annual growth rate (CAGR), from $226K to $245K.
- What does business segments — other mean?
- Captures miscellaneous operational expenses that do not fall into primary categories like clinical, nonclinical, or personnel costs. These expenditures typically include general administrative support, facility overhead, or minor project-specific costs. Monitoring this category helps identify unexpected or ancillary costs that may impact the overall segment budget.